SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
SIGA Technologies (Nasdaq: SIGA) $11.40. Today announced that the Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services, has advised that it is issuing a new Request for Proposal, number 11-100-SOL-00007, seeking to procure 1.7 million courses of a smallpox antiviral. The Request for Proposal also proposes that the contract would contain an option to procure up to 12 million additional courses. BARDA's previous Request for Proposal on this subject, number 09-35, has been cancelled. Responses to the new Request for Proposal are due February 28, 2011.
What They Do: SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense.
Sonic Automotive (NYSE: SAH) $14.80. Today announced that its Board of Directors approved a quarterly dividend of $0.025 per share payable in cash for shareholders of record on March 15, 2011. The dividend will be payable April 15, 2011.
What They Do: Sonic Automotive is one of the nation's largest automotive retailers.
Derma Sciences (Nasdaq: DSCI) $9.66. Today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure. This contract, which is part of the HHS radiological and nuclear threats preparedness strategy, could be extended for a total of five years and up to a total of $14 million. Derma Sciences recently announced positive Phase 2 data in the use of DSC127 in diabetic foot ulcer healing, in which 54% of wounds healed completely in 12 weeks, compared with only 33% of wounds in patients receiving placebo and best standard of care in the intent to treat populations.
What They Do: Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, pharmaceutical wound care products, advanced wound care dressings and traditional dressings.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
